PTC Therapeutics (PTCT) News Today $50.24 -0.15 (-0.29%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on ThursdayPTC Therapeutics (NASDAQ:PTCT) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=334330)February 21 at 1:32 AM | marketbeat.comPTC Therapeutics to Participate in Upcoming Investor ConferencesFebruary 20 at 8:00 AM | prnewswire.comVontobel Holding Ltd. Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Vontobel Holding Ltd. acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,532 shares of the biopFebruary 20 at 3:26 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $58.85 Consensus Target Price from BrokeragesFebruary 20 at 1:31 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $63.00Royal Bank of Canada lifted their target price on PTC Therapeutics from $60.00 to $63.00 and gave the company an "outperform" rating in a research report on Tuesday.February 19 at 4:09 PM | marketbeat.comPTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's AtaxiaFebruary 19 at 7:00 AM | prnewswire.comRoyal Bank of Canada Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceFebruary 19 at 3:47 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by StockNews.comFebruary 19 at 1:43 AM | americanbankingnews.comStockNews.com Downgrades PTC Therapeutics (NASDAQ:PTCT) to HoldStockNews.com cut shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday.February 18 at 10:06 PM | marketbeat.comPTC Therapeutics (PTCT) Gets a Buy from RBC CapitalFebruary 18 at 8:40 AM | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Hold" from BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has earned an average rating of "Hold" from the fifteen research firms that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, eiFebruary 17, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $45.00 at CitigroupFebruary 15, 2025 | americanbankingnews.comApollon Wealth Management LLC Has $399,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Apollon Wealth Management LLC lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,839 shares of the biopharmaceutical company's stFebruary 14, 2025 | marketbeat.comPTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial ResultsFebruary 13, 2025 | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Given New $45.00 Price Target at CitigroupCitigroup increased their price target on PTC Therapeutics from $32.00 to $45.00 and gave the company a "sell" rating in a research note on Wednesday.February 12, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Rating Increased to Buy at StockNews.comStockNews.com raised PTC Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday.February 7, 2025 | marketbeat.comPTC Therapeutics (PTCT) Receives a Buy from Morgan StanleyFebruary 6, 2025 | markets.businessinsider.comCantor Fitzgerald Issues Negative Estimate for PTCT EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for PTC Therapeutics in a report issued on Monday, February 3rd. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical compaFebruary 5, 2025 | marketbeat.comPTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challengesFebruary 4, 2025 | msn.comPTC Therapeutics price target raised to $113 from $76 at Cantor FitzgeraldFebruary 3, 2025 | markets.businessinsider.comWhy PTC Therapeutics (PTCT) Stock Is Rallying TodayFebruary 3, 2025 | msn.comPTC Therapeutics (NASDAQ:PTCT) Trading Up 6.1% on Analyst UpgradePTC Therapeutics (NASDAQ:PTCT) Stock Price Up 6.1% on Analyst UpgradeFebruary 3, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $113.00Cantor Fitzgerald lifted their target price on shares of PTC Therapeutics from $76.00 to $113.00 and gave the company an "overweight" rating in a report on Monday.February 3, 2025 | marketbeat.comCantor Fitzgerald lifts PTC Therapeutics stock target to $113February 3, 2025 | msn.comCowen raises PTC Therapeutics stock price target to $50January 29, 2025 | msn.comPTC Therapeutics (PTCT) Receives a Hold from TD CowenJanuary 29, 2025 | markets.businessinsider.comCantor Fitzgerald Comments on PTCT FY2025 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of PTC Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnJanuary 22, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for PTCT FY2024 Earnings?PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for shares of PTC Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical compaJanuary 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Decreases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Assenagon Asset Management S.A. trimmed its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 439,670 shares of the biopharmaceutical compaJanuary 18, 2025 | marketbeat.comCantor Fitzgerald Has Positive View of PTCT FY2024 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for PTC Therapeutics in a report issued on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company wilJanuary 17, 2025 | marketbeat.comWilliam Blair Has Optimistic Outlook of PTCT FY2024 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - William Blair increased their FY2024 earnings estimates for shares of PTC Therapeutics in a report released on Monday, January 13th. William Blair analyst S. Corwin now expects that the biopharmaceutical company will post earnings of ($5.33) peJanuary 16, 2025 | marketbeat.comPTC Therapeutics price target lowered at Cantor Fitzgerald, a top pick in 2025January 15, 2025 | markets.businessinsider.comPTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $76.00 at Cantor FitzgeraldCantor Fitzgerald lowered their target price on PTC Therapeutics from $80.00 to $76.00 and set an "overweight" rating on the stock in a report on Wednesday.January 15, 2025 | marketbeat.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 13, 2025 | prnewswire.comPTC Therapeutics sees FY25 revenue $600M-$800MJanuary 13, 2025 | markets.businessinsider.comPTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31MJanuary 13, 2025 | markets.businessinsider.comPTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $36,725.40 in StockJanuary 11, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 810 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 810 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total transaction of $36,725.40. Following the completion of the transaction, the executive vice president now directly owns 79,849 shares of the company's stock, valued at approximately $3,620,353.66. This represents a 1.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.January 10, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 1,265 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) insider Neil Gregory Almstead sold 1,265 shares of PTC Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $57,355.10. Following the sale, the insider now directly owns 104,783 shares in the company, valued at approximately $4,750,861.22. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 10, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CAO Christine Marie Utter sold 1,291 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $58,533.94. Following the sale, the chief accounting officer now directly owns 65,983 shares of the company's stock, valued at approximately $2,991,669.22. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.January 10, 2025 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells 1,543 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 1,543 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $69,959.62. Following the sale, the vice president now directly owns 108,846 shares of the company's stock, valued at $4,935,077.64. This represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.January 10, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $72,498.66 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Eric Pauwels sold 1,599 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $72,498.66. Following the transaction, the chief executive officer now owns 88,941 shares of the company's stock, valued at $4,032,584.94. This represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 10, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)JPMorgan Chase & Co. decreased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 17.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 562,781 shares of the biopharmaceutical company's stock after selling 118,152 shareJanuary 9, 2025 | marketbeat.comPTC Therapeutics price target lowered to $58 from $63 at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 8,279 Shares of StockJanuary 4, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $373,879.64 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew B. Klein sold 8,279 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $45.16, for a total value of $373,879.64. Following the completion of the transaction, the chief executive officer now directly owns 217,528 shares of the company's stock, valued at $9,823,564.48. This trade represents a 3.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 3, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Hold" by AnalystsPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been assigned an average rating of "Hold" from the fifteen analysts that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have assignedDecember 29, 2024 | marketbeat.comPTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | prnewswire.comGeode Capital Management LLC Buys 10,886 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Geode Capital Management LLC boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,798,666 shares of the biopharmaceutDecember 22, 2024 | marketbeat.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.500.60▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼136▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News GMAB News ITCI News VTRS News MRNA News RDY News PCVX News SRPT News QGEN News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
